Richard T Davey

Richard T Davey

UNVERIFIED PROFILE

Are you Richard T Davey?   Register this Author

Register author
Richard T Davey

Richard T Davey

Publications by authors named "Richard T Davey"

Are you Richard T Davey?   Register this Author

84Publications

1032Reads

-Profile Views

New filovirus disease classification and nomenclature.

Nat Rev Microbiol 2019 May;17(5):261-263

World Health Organization Regional Office for Africa, Brazzaville, Democratic Republic of the Congo.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41579-019-0187-4DOI Listing
May 2019

Evaluating Promising Investigational Medical Countermeasures: Recommendations in the Absence of Guidelines.

Health Secur 2019 Jan/Feb;17(1):46-53. Epub 2019 Feb 6.

Mark G. Kortepeter, MD, MPH, is Professor, Department of Epidemiology, University of Nebraska College of Public Health, Omaha, NE.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/hs.2018.0092DOI Listing
February 2019

The Past Need Not Be Prologue: Recommendations for Testing and Positioning the Most-Promising Medical Countermeasures for the Next Outbreak of Ebola Virus Infection.

J Infect Dis 2018 Nov;218(suppl_5):S690-S697

Division of Clinical Research, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/infdis/jiy334DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6249585PMC
November 2018

Ebola virus disease: an update on post-exposure prophylaxis.

Lancet Infect Dis 2018 06 15;18(6):e183-e192. Epub 2017 Nov 15.

Department of Infection, Royal Free London NHS Foundation Trust, London, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1473-3099(17)30677-1DOI Listing
June 2018

Safety, tolerability, and pharmacokinetics of radavirsen (AVI-7100), an antisense oligonucleotide targeting influenza a M1/M2 translation.

Br J Clin Pharmacol 2018 Jan 22;84(1):25-34. Epub 2017 Sep 22.

National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bcp.13405DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5736848PMC
January 2018

Cardiac MRI Findings Suggest Myocarditis in Severe Ebola Virus Disease.

JACC Cardiovasc Imaging 2017 06 17;10(6):711-713. Epub 2016 Aug 17.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jcmg.2016.06.004DOI Listing
June 2017

colonization in asthmatic patients not receiving oral corticosteroid therapy.

J Investig Med 2017 04 13;65(4):800-802. Epub 2017 Feb 13.

Critical Care Medicine Department, National Institutes of Health Clinical Center, Bethesda, Maryland, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/jim-2016-000381DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6309956PMC
April 2017

Longitudinal peripheral blood transcriptional analysis of a patient with severe Ebola virus disease.

Sci Transl Med 2017 04;9(385)

Viral Pathogenesis and Evolution Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/scitranslmed.aai9321DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5497219PMC
April 2017

Trial of ZMapp for Ebola Virus Infection.

N Engl J Med 2017 02;376(7):700-701

National Institute of Allergy and Infectious Diseases, Bethesda, MD

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1614625DOI Listing
February 2017

A Recombinant Vesicular Stomatitis Virus Ebola Vaccine.

N Engl J Med 2017 01 1;376(4):330-341. Epub 2015 Apr 1.

From the Walter Reed Army Institute of Research (J.A.R., K.M.P., A.R.C., J.E.M., R.C.R., J.W.B., P.S.T., S.A.R., H.R.H., M.S., L.L.J., S.A.P., N.L.M., S.J.T.) and Naval Medical Research Center (R.L.G.), Silver Spring, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research (J.H.B., W.J.), and the U.S. Army Medical Research Institute of Infectious Diseases (M.L.W., M.D.J., S.A.K., N.V.D., K.S.S., J.W.H., P.M.S.), Frederick, and the National Institute of Allergy and Infectious Diseases (NIAID) (J.V., Z.H., P.M., H.C.L., R.T.D.) and NIAID Vaccine Research Center (O.T.M., Y.Z., D.A.S., J.E.L., B.S.G., N.J.S.), Bethesda - all in Maryland; the Public Health Agency of Canada, Ottawa (J.B.A.); and BioProtection Systems-NewLink Genetics, Ames, IA (B.K.M., T.P.M., W.J.R., C.J.L.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1414216DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5408576PMC
January 2017

Human antibody repertoire after VSV-Ebola vaccination identifies novel targets and virus-neutralizing IgM antibodies.

Nat Med 2016 12 31;22(12):1439-1447. Epub 2016 Oct 31.

Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nm.4201DOI Listing
December 2016

Evaluation of Antihemagglutinin and Antineuraminidase Antibodies as Correlates of Protection in an Influenza A/H1N1 Virus Healthy Human Challenge Model.

MBio 2016 Apr 19;7(2):e00417-16. Epub 2016 Apr 19.

Viral Pathogenesis and Evolution Section, Laboratory of Infectious Diseases, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1128/mBio.00417-16DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4959521PMC
April 2016

Clinical Management of Ebola Virus Disease in the United States and Europe.

N Engl J Med 2016 Feb;374(7):636-46

From the Centers for Disease Control and Prevention (T.M.U., J.G.) and the Division of Infectious Diseases, Emory University School of Medicine (A.K.M.) - both in Atlanta; the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD (R.T.D.); Texas Health Presbyterian Hospital Dallas, Dallas (A.M.L.); the Department of Infectious Diseases, University Hospital Frankfurt, Frankfurt am Main (T.W.), the First Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg (S.S.), and Leipzig Treatment Center for Highly Contagious Diseases, Klinikum St. Georg, Leipzig (T.G.) - all in Germany; the Division of Infectious Diseases and Laboratory of Virology, Geneva University Hospitals, Geneva (P.V.); the Department of Infection, Royal Free London NHS Foundation Trust, London (M.J.); the Internal Medicine Department, Infectious Diseases Unit Madrid, Hospital La Paz-Carlos III IdiPAZ, Madrid (J.R.A.); New York University School of Medicine-Bellevue Hospital Center, New York (L.E.); University of Nebraska Medical Center, Omaha (A.L.H.); the Departments of Infectious Diseases and Acute Medicine, Oslo University Hospital, Oslo (A.B.B.); Lazzaro Spallanzani National Institute for Infectious Diseases, Rome (G.I.); the Infectious and Tropical Diseases Department, Bégin Military Hospital, Saint-Mandé, France (C.R.); and the Department of Internal Medicine and Infectious Diseases, University Medical Center Utrecht, Utrecht, the Netherlands (A.I.M.H.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1504874DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4972324PMC
February 2016

Response.

Chest 2015 Aug;148(2):e65

Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00123692155037
Publisher Site
http://dx.doi.org/10.1378/chest.15-0986DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4524333PMC
August 2015

Ethical and practical considerations in providing critical care to patients with Ebola virus disease.

Chest 2015 Jun;147(6):1460-1466

Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1378/chest.15-0278DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4451704PMC
June 2015

Challenges in managing patients who have suspected or confirmed Ebola virus infection at the National Institutes of Health.

Infect Control Hosp Epidemiol 2015 Jun;36(6):623-6

3Office of the Deputy Director for Clinical Care,Clinical Center,National Institutes of Health,Bethesda,Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1017/ice.2015.60DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583637PMC
June 2015

Validation of the wild-type influenza A human challenge model H1N1pdMIST: an A(H1N1)pdm09 dose-finding investigational new drug study.

Clin Infect Dis 2015 Mar 20;60(5):693-702. Epub 2014 Nov 20.

Viral Pathogenesis and Evolution Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/cid/ciu924DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4342672PMC
March 2015

Markers of inflammation and activation of coagulation are associated with anaemia in antiretroviral-treated HIV disease.

AIDS 2014 Jul;28(12):1791-6

aCentre for Health and Infectious Diseases Research (CHIP), Department of Infectious Diseases and Reumathology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark bThrombosis & Atherosclerosis Research Institute and McMaster University, Hamilton, Ontario, Canada cDepartment of Biostatistics dDepartment of Medicine, University of Minnesota eHennepin County Medical Center, Minneapolis, Minnesota, USA fINSERM U955 Equipe 16 gVaccine Research Institute (VRI), Université Paris Est Créteil, Faculté de Médecine hService d'Immunologie Clinique, Hôpital Henri Mondor, AP-HP, Créteil, France iNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA jResearch Department of Infection and Population Health, University College London, London, UK kDepartment of Medicine, University of California, San Francisco, California, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/QAD.0000000000000344DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4499102PMC
July 2014

The effect of intermittent IL-2 therapy on CD4 T cells in the gut in HIV-1-infected patients.

J Acquir Immune Defic Syndr 2011 Apr;56(4):340-3

Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/QAI.0b013e31820bf84cDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073743PMC
April 2011

Targeting pandemic influenza: a primer on influenza antivirals and drug resistance.

J Antimicrob Chemother 2010 Jun 7;65(6):1086-93. Epub 2010 Apr 7.

NexBio, Inc., San Diego, CA, USA.

View Article

Download full-text PDF

Source
https://academic.oup.com/jac/article-lookup/doi/10.1093/jac/
Publisher Site
http://dx.doi.org/10.1093/jac/dkq100DOI Listing
June 2010

Triage and management of accidental laboratory exposures to biosafety level-3 and -4 agents.

Biosecur Bioterror 2009 Jun;7(2):135-43

Integrated Research Facility, National Institute of Allergy and Infectious Diseases, Frederick, Maryland 21702, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/bsp.2009.0002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2749272PMC
June 2009

Pharmacokinetics and tolerability of oseltamivir combined with probenecid.

Antimicrob Agents Chemother 2008 Sep 16;52(9):3013-21. Epub 2008 Jun 16.

US Department of Veterans Affairs, Office of Public Health and Environmental Hazards, Washington, DC, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1128/AAC.00047-08DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2533494PMC
September 2008

Idiopathic CD4+ lymphocytopenia: natural history and prognostic factors.

Blood 2008 Jul 2;112(2):287-94. Epub 2008 May 2.

Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2007-12-127878DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2442741PMC
July 2008

Limitations of using a single postdose midazolam concentration to predict CYP3A-mediated drug interactions.

J Clin Pharmacol 2008 Jun 16;48(6):671-80. Epub 2008 Apr 16.

Clinical Pharmacokinetics Research Laboratory, National Institutes of Health, Clinical Center Pharmacy Department, Bldg 10, Room 1N 257, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0091270008317305DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2658757PMC
June 2008

Effect of Ginkgo biloba extract on lopinavir, midazolam and fexofenadine pharmacokinetics in healthy subjects.

Curr Med Res Opin 2008 Feb;24(2):591-9

Office of Clinical Pharmacology, Center for Drug Evaluation and Research, US Food and Drug Administration, New Hampshire Ave., Silver Spring, MD 20901, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1185/030079908X260871 DOI Listing
February 2008

CD4+ T cell responses to interleukin-2 administration in HIV-infected patients are directly related to the baseline level of immune activation.

J Infect Dis 2007 Sep 16;196(5):677-83. Epub 2007 Jul 16.

National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1086/520087DOI Listing
September 2007

Changes in paracrine interleukin-2 requirement, CCR7 expression, frequency, and cytokine secretion of human immunodeficiency virus-specific CD4+ T cells are a consequence of antigen load.

J Virol 2007 Mar 20;81(6):2713-25. Epub 2006 Dec 20.

Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 10 Center Drive, MSC 1876, Bethesda, MD 20892-1876, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1128/JVI.01830-06DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1865970PMC
March 2007

Reporting and evaluation of HIV-related clinical endpoints in two multicenter international clinical trials.

HIV Clin Trials 2006 May-Jun;7(3):125-41

Department of Epidemiology and Community Health, University of Minnesota, 1300 South Second Street, Minneapolis, MN 55454, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1310/7MER-XFA7-1762-E2WRDOI Listing
September 2006

Straying from the path?

Authors:
Richard T Davey

Curr Opin HIV AIDS 2006 Jan;1(1):40-2

National Institutes of Health, Bethesda, Maryland, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/01.COH.0000194100.82320.abDOI Listing
January 2006

BAY 50-4798, a novel, high-affinity receptor-specific recombinant interleukin-2 analog, induces dose-dependent increases in CD25 expression and proliferation among unstimulated, human peripheral blood mononuclear cells in vitro.

Clin Immunol 2004 Dec;113(3):248-55

Clinical and Molecular Retrovirology Section, Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clim.2004.07.009DOI Listing
December 2004

Graves' disease after interleukin-2 therapy in a patient with human immunodeficiency virus infection.

Thyroid 2004 Dec;14(12):1097-102

Joint Endocrinology, Diabetes & Metabolism Fellowship at Baylor College of Medicine/The University of Texas-M.D. Anderson Cancer Center, Houston 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/thy.2004.14.1097DOI Listing
December 2004

IL-2-induced CD4+ T-cell expansion in HIV-infected patients is associated with long-term decreases in T-cell proliferation.

Blood 2004 Aug 13;104(3):775-80. Epub 2004 Apr 13.

Clinical and Molecular Retrovirology Section, Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/cgi/doi/10.1182/blood-2003-12-43
Publisher Site
http://dx.doi.org/10.1182/blood-2003-12-4355DOI Listing
August 2004

A proof-of-concept study of short-cycle intermittent antiretroviral therapy with a once-daily regimen of didanosine, lamivudine, and efavirenz for the treatment of chronic HIV infection.

J Infect Dis 2004 Jun 10;189(11):1974-82. Epub 2004 May 10.

Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, United States Department of Health and Human Services, Bethesda, Maryland 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1086/386344DOI Listing
June 2004

Induction and maintenance therapy with intermittent interleukin-2 in HIV-1 infection.

Blood 2004 May 15;103(9):3282-6. Epub 2004 Jan 15.

Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2003-09-3283DOI Listing
May 2004

A randomized, double-blinded, placebo-controlled trial of intermittent administration of interleukin-2 and prednisone in subjects infected with human immunodeficiency virus.

J Infect Dis 2003 Aug 31;188(4):531-6. Epub 2003 Jul 31.

Office of the Clinical Director, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland 20892, US.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1086/377285DOI Listing
August 2003

Suppression of cerebrospinal fluid HIV burden in antiretroviral naive patients on a potent four-drug antiretroviral regimen.

AIDS 2003 May;17(8):1167-72

Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, U.S. Department of Health and Human Services, Bethesda, Maryland 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/01.aids.0000060391.18106.95DOI Listing
May 2003

Long-term effects of intermittent interleukin 2 therapy in patients with HIV infection: characterization of a novel subset of CD4(+)/CD25(+) T cells.

Blood 2002 Sep;100(6):2159-67

Clinical and Molecular Retrovirology Section, Labotratory of Immunoregulation, National Institute of Allergy and Infectious Diseases/NIH, Building 10, Room 11S-231, 10 Center Drive, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
September 2002

High prevalence of osteonecrosis of the femoral head in HIV-infected adults.

Ann Intern Med 2002 Jul;137(1):17-25

Critical Care Medicine Department, Clinical Center, Building 10, Room 7D43, MSC1662, National Institutes of Health, Bethesda, MD 20892-1662, USA.

View Article

Download full-text PDF

Source
July 2002

Pilot study of the effects of intermittent interleukin-2 on human immunodeficiency virus (HIV)-specific immune responses in patients treated during recently acquired HIV infection.

J Infect Dis 2002 Jan 14;185(1):61-8. Epub 2001 Dec 14.

Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1086/338123DOI Listing
January 2002